ClinicalTrials.gg
CompletedNCT01327053BOLTUpdated Aug 28, 2019Results posted

A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

A Phase 2 interventional study of LDE225 in Basal Cell Carcinoma, sponsored by Novartis Pharmaceuticals. Completed at 62 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.

Enrollment
11th of 139
230 · median 40
Started
2011
with 7 others
Phase 2
46 of 171
6 open now
Registered
54th of 171
by date

Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 11th largest by enrollment of the 139 interventional ones that give a count, is one of 8 that started in 2011, is one of 46 in phase 2, and was the 54th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Carcinoma, Basal Cell with a site in United States, or all of them as a file.
02

Study summary

This study assessed the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.

03

Conditions studied

  • Basal Cell Carcinoma

Keywords

  • locally advanced basal cell carcinoma
  • metastatic basal cell carcinoma
  • LDE225
  • sonidegib
  • Basel Cell Carcinoma (BCC)
  • skin cancer
  • Basel Cell Carcinoma
  • BCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with locally advanced BCC and BCC
  • Patients with adequate bone marrow, liver, and renal function

Exclusion criteria

Exclusion Criteria:

  • Patients who had had major surgery within 4 weeks of initiation of study medication
  • Patients unable to take oral drugs or with lack of physical integrity of the upper gastrointestinal tract, or known malabsorption syndromes.
  • Patients with concurrent medical conditions that may interfere or potentially affect the interpretation of the study.
  • Patients with neuromuscular disorders or are on concurrent treatment with drugs that may cause muscle damage.
  • Patients who were on concurrent therapy with other anti-neoplastic agents.
  • Patients who had taken part in an experimental drug within 4 weeks of initiation of study medication.
  • Pregnant or nursing (lactating) women
  • Women of child bearing potential unwilling to use 2 forms of highly effective throughout the study and for 3 months after the last treatment
  • Fertile males not willing to use condoms throughout the study and for 3 months after the last treatment.
  • Patients who were unwilling or unable to comply with the protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
230 participants (actual)

Study arms

  • Experimental
    LDE225 200 mg

    The study was double blinded and enrolled at least 50 evaluable patients in the 200 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.

    Drug: LDE225

  • Experimental
    LDE225 800 mg

    The study was double blinded and enrolled at least 100 evaluable patients in the 800 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.

    Drug: LDE225

Interventions

  • DrugLDE225

    LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.

    Also known as: Sonidegib

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell Carcinoma (mBCC)) Per Primary Efficacy Analysis Set (pEAS)

    ORR is the percentage of patient's objective response (ORR) by 6 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 6 months after starting LDE225 treatment.Treatment with sonidegib was considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

    Time frame: 6 months

  2. Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (Metastatic Basal Cell Carcinoma (mBCC)) Per Full Analysis Set (FAS)

    ORR is the percentage of patient's objective response (ORR) by 6 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 6 months after starting LDE225 treatment.Treatment with sonidegib was to be considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

    Time frame: 6 months

Secondary outcomes

  1. Duration of Response (DoR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)

    Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. Progressive disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.

    Time frame: 42 months

  2. Duration of Response (DoR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)

    Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Median DoR for patients with laBCC was non-estimable for both treatment arms. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

    Time frame: 42 months

  3. Complete Response Rate (CRR) Per Central Review (pEAS)

    Rate of complete response is the percentage of patients with best overall response of complete response (CR) after starting LDE225 treatment. The rate of CR was determined according to mRECIST for laBCC and RECIST 1.1 for mBCC. Patients with best overall response of 'Unknown" were treated as non responders. Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

    Time frame: 42 months

  4. Complete Response Rate (CRR) Per Central Review (FAS)

    Rate of complete response is the proportion of patients with best overall response of complete response (CR) after starting LDE225 treatment. The rate of CR will be determined according to mRECIST for laBCC and RECIST 1.1 for mBCC. Patients with best overall response of 'Unknown" will be treated as non responders

    Time frame: 6 months

  5. Progression-free Survival (PFS) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)

    Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.

    Time frame: 42 months

  6. Progression-free Survival (PFS) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)

    Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment.

    Time frame: 42 months

  7. Time to Tumor Response (TTR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)

    Time to tumor response (TTR) is defined as the time from date of enrollment to the date of first documented tumor response (CR or PR). PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

    Time frame: 42 months

  8. Time to Tumor Response (TTR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)

    Time to tumor response (TTR) is defined as the time from date of enrollment to the date of first documented tumor response (CR or PR). PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

    Time frame: 42 months

  9. Objective Response Rate (ORR) Based on Site Investigator Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell Carcinoma (mBCC)) Per Primary Efficacy Analysis Set (pEAS)

    ORR is the percentage of patient's objective response (ORR) by 42 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 42 months after starting LDE225 treatment. Treatment with sonidegib was considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

    Time frame: 42 months

  10. Objective Response Rate (ORR) Based on Site Investigator Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (Metastatic Basal Cell Carcinoma (mBCC)) Per Full Analysis Set (FAS)

    ORR is the percentage of patient's objective response (ORR) by 6 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 42 months after starting LDE225 treatment.Treatment with sonidegib was to be considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

    Time frame: 42 months

  11. Duration of Response (DoR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)

    Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. Progressive disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.

    Time frame: 42 months

  12. Duration of Response (DoR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)

    Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

    Time frame: 42 months

  13. Progression-free Survival (PFS) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)

    Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.

    Time frame: 42 months

  14. Time to Tumor Response (TTR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)

    Time to tumor response (TTR) is defined as the time from date of enrollment to the date of first documented tumor response (CR or PR). PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

    Time frame: 42 months

  15. Plasma Concentration of Sonidegib (LDE225)

    Blood PK samples were collected either by direct venipuncture or an indwelling cannula inserted in a forearm vein for the determination of trough (Cmin) plasma concentrations of sonidegib and its main circulating metabolite, LGE899, from all patients who enrolled in the study. Blood was collected in Weeks 1, 3, 5, 9 (pre-dose), and subsequently pre-dose every 4 weeks up to Week 21, and every 12 weeks thereafter up to week 69.

    Time frame: Weeks 1, 3, 5, 9, 13, 17, 21, 33, 45, 57, 69

  16. Overall Survival (OS)

    OS is defined as the time from date of randomization to date of death due to any cause or the last date that a patient was known to be alive (censored observation) as of the data cut-off.

    Time frame: 42 months

07

Results

Posted Nov 23, 2015
Limitations and caveats
230 patients evaluated in the Full Analysis Set: 79 randomized to LDE225 (Sonidegib) 200mg group \& 151 randomized to LDE225 800mg group. 1 patient randomized to the 800mg group did not receive study treatment \& thus was not counted in the Safety Set.

Participant flow

Randomization was stratified across the two treatment arms according to the stage of disease (laBCC or mBCC), histological subtype (non-aggressive or aggressive for laBCC patients) and the regions (Australia, Europe, and North America).

Participant flow — Overall Study
MilestoneLDE225 (Sonidegib) 200 mgLDE225 (Sonidegib) 800 mg
Started79151
Untreated01
Patients cont. to next phase of trial5289
Survival follow-up3349
Post-treatment follow-up1940
Completed00
Not completed79151
Withdrew: Adverse event2357
Withdrew: Patient/guardian decision1135
Withdrew: Physician decision1014
Withdrew: Death15
Withdrew: Lost to follow-up24
Withdrew: Non-compliance with study treatment05
Withdrew: Study terminated by sponsor13
Withdrew: Progressive disease3126
Withdrew: Protocol violation01
Withdrew: Untreated01

Outcome measures

PrimaryObjective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell Carcinoma (mBCC)) Per Primary Efficacy Analysis Set (pEAS)

ORR is the percentage of patient's objective response (ORR) by 6 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 6 months after starting LDE225 treatment.Treatment with sonidegib was considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

Time frame:
6 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell Carcinoma (mBCC)) Per Primary Efficacy Analysis Set (pEAS)
Percentage of participantsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell Carcinoma (mBCC)) Per Primary Efficacy Analysis Set (pEAS)42.9 (27.7 to 59.0)37.6 (27.8 to 48.3)15.4 (1.9 to 45.4)17.4 (5.0 to 38.8)
PrimaryObjective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (Metastatic Basal Cell Carcinoma (mBCC)) Per Full Analysis Set (FAS)

ORR is the percentage of patient's objective response (ORR) by 6 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 6 months after starting LDE225 treatment.Treatment with sonidegib was to be considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

Time frame:
6 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (Metastatic Basal Cell Carcinoma (mBCC)) Per Full Analysis Set (FAS)
Percentage of participantsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (Metastatic Basal Cell Carcinoma (mBCC)) Per Full Analysis Set (FAS)47.0 (34.6 to 59.7)35.2 (26.9 to 44.1)15.4 (1.9 to 45.4)17.4 (5.0 to 38.8)
SecondaryDuration of Response (DoR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)

Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. Progressive disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.

Time frame:
42 months
Reported as:
Median · Months
Duration of Response (DoR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)
MonthsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Duration of Response (DoR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)12.9 (NA to NA)23.7 (10.8 to 29.6)24.0 (NA to NA)NA (NA to NA)
SecondaryDuration of Response (DoR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)

Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Median DoR for patients with laBCC was non-estimable for both treatment arms. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

Time frame:
42 months
Reported as:
Median · Months
Duration of Response (DoR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)
MonthsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Duration of Response (DoR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)26.1 (NA to NA)23.3 (12.2 to 29.6)24.0 (NA to NA)NA (NA to NA)
SecondaryComplete Response Rate (CRR) Per Central Review (pEAS)

Rate of complete response is the percentage of patients with best overall response of complete response (CR) after starting LDE225 treatment. The rate of CR was determined according to mRECIST for laBCC and RECIST 1.1 for mBCC. Patients with best overall response of 'Unknown" were treated as non responders. Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

Time frame:
42 months
Reported as:
Number · Percentage of participants
Complete Response Rate (CRR) Per Central Review (pEAS)
Percentage of participantsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Complete Response Rate (CRR) Per Central Review (pEAS)4.8 (0.6 to 16.2)2.2 (0.3 to 7.6)0.0 (0.0 to 24.7)0.0 (0.0 to 14.8)
SecondaryComplete Response Rate (CRR) Per Central Review (FAS)

Rate of complete response is the proportion of patients with best overall response of complete response (CR) after starting LDE225 treatment. The rate of CR will be determined according to mRECIST for laBCC and RECIST 1.1 for mBCC. Patients with best overall response of 'Unknown" will be treated as non responders

Time frame:
6 months
Reported as:
Number · Percentage of participants
Complete Response Rate (CRR) Per Central Review (FAS)
Percentage of participantsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Complete Response Rate (CRR) Per Central Review (FAS)3.0 (0.4 to 10.5)0.0 (0.0 to 2.8)0.0 (0.0 to 24.7)0.0 (0.0 to 14.8)
SecondaryProgression-free Survival (PFS) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)

Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.

Time frame:
42 months
Reported as:
Median · Months
Progression-free Survival (PFS) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)
MonthsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Progression-free Survival (PFS) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)19.0 (NA to NA)19.4 (13.8 to 30.5)13.1 (5.6 to 33.1)11.1 (7.3 to 16.6)
SecondaryProgression-free Survival (PFS) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)

Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment.

Time frame:
42 months
Reported as:
Median · Months
Progression-free Survival (PFS) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)
MonthsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Progression-free Survival (PFS) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)22.1 (NA to NA)24.9 (19.2 to 33.4)13.1 (5.6 to 33.1)11.1 (7.3 to 16.6)
SecondaryTime to Tumor Response (TTR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)

Time to tumor response (TTR) is defined as the time from date of enrollment to the date of first documented tumor response (CR or PR). PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

Time frame:
42 months
Reported as:
Median · Months
Time to Tumor Response (TTR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)
MonthsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Time to Tumor Response (TTR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)4.0 (3.7 to 5.6)3.7 (2.0 to 5.5)9.2 (NA to NA)1.0 (1.0 to 2.1)
SecondaryTime to Tumor Response (TTR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)

Time to tumor response (TTR) is defined as the time from date of enrollment to the date of first documented tumor response (CR or PR). PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

Time frame:
42 months
Reported as:
Median · Months
Time to Tumor Response (TTR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)
MonthsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Time to Tumor Response (TTR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)4.0 (3.7 to 5.6)3.7 (2.0 to 5.5)9.2 (NA to NA)1.0 (1.0 to 2.1)
SecondaryObjective Response Rate (ORR) Based on Site Investigator Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell Carcinoma (mBCC)) Per Primary Efficacy Analysis Set (pEAS)

ORR is the percentage of patient's objective response (ORR) by 42 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 42 months after starting LDE225 treatment. Treatment with sonidegib was considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

Time frame:
42 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Based on Site Investigator Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell Carcinoma (mBCC)) Per Primary Efficacy Analysis Set (pEAS)
Percentage of participantsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Objective Response Rate (ORR) Based on Site Investigator Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell Carcinoma (mBCC)) Per Primary Efficacy Analysis Set (pEAS)71.4 (55.4 to 84.3)61.3 (50.6 to 71.2)23.1 (5.0 to 53.8)34.8 (16.4 to 57.3)
SecondaryObjective Response Rate (ORR) Based on Site Investigator Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (Metastatic Basal Cell Carcinoma (mBCC)) Per Full Analysis Set (FAS)

ORR is the percentage of patient's objective response (ORR) by 6 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 42 months after starting LDE225 treatment.Treatment with sonidegib was to be considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

Time frame:
42 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Based on Site Investigator Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (Metastatic Basal Cell Carcinoma (mBCC)) Per Full Analysis Set (FAS)
Percentage of participantsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Objective Response Rate (ORR) Based on Site Investigator Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (Metastatic Basal Cell Carcinoma (mBCC)) Per Full Analysis Set (FAS)71.2 (58.7 to 81.7)58.6 (49.6 to 67.2)23.1 (5.0 to 53.8)34.8 (16.4 to 57.3)
SecondaryDuration of Response (DoR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)

Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. Progressive disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.

Time frame:
42 months
Reported as:
Median · Months
Duration of Response (DoR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)
MonthsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Duration of Response (DoR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)18.2 (12.9 to 23.0)26.0 (15.7 to 47.3)18.1 (17.7 to 18.4)10.2 (NA to NA)
SecondaryDuration of Response (DoR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)

Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

Time frame:
42 months
Reported as:
Median · Months
Duration of Response (DoR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)
MonthsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Duration of Response (DoR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)15.7 (12.0 to 20.2)26.0 (18.3 to 47.3)18.1 (17.7 to 18.4)10.2 (NA to NA)
SecondaryProgression-free Survival (PFS) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)

Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.

Time frame:
42 months
Reported as:
Median · Months
Progression-free Survival (PFS) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)
MonthsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Progression-free Survival (PFS) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)20.1 (14.8 to 23.8)28.0 (19.4 to 49.8)13.1 (9.2 to 19.4)14.3 (11.1 to 17.0)
SecondaryTime to Tumor Response (TTR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)

Time to tumor response (TTR) is defined as the time from date of enrollment to the date of first documented tumor response (CR or PR). PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.

Time frame:
42 months
Reported as:
Median · Months
Time to Tumor Response (TTR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)
MonthsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Time to Tumor Response (TTR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)1.9 (1.8 to 3.9)1.8 (1.1 to 2.0)1.0 (0.9 to 3.7)2.7 (1.0 to 5.6)
SecondaryPlasma Concentration of Sonidegib (LDE225)

Blood PK samples were collected either by direct venipuncture or an indwelling cannula inserted in a forearm vein for the determination of trough (Cmin) plasma concentrations of sonidegib and its main circulating metabolite, LGE899, from all patients who enrolled in the study. Blood was collected in Weeks 1, 3, 5, 9 (pre-dose), and subsequently pre-dose every 4 weeks up to Week 21, and every 12 weeks thereafter up to week 69.

Time frame:
Weeks 1, 3, 5, 9, 13, 17, 21, 33, 45, 57, 69
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Sonidegib (LDE225)
ng/mLLDE225 200 mg qdLDE225 800 mg qd
Week 1 (0 h (pre-dose))NA ± NANA ± NA
Week 3 (0 h (pre-dose))207.76 ± 78.29586.76 ± 97.13
Week 5 (0 h (pre-dose))372.26 ± 68.891012.63 ± 70.42
Week 9 (0 h (pre-dose))559.29 ± 67.301353.06 ± 63.43
Week 13 (0 h (pre-dose))714.01 ± 60.791443.84 ± 61.57
Week 17 (0 h (pre-dose))688.93 ± 64.431574.21 ± 59.88
Week 17 (1 h (post-dose))841.78 ± 52.571803.74 ± 39.47
Week 17 (2 h (post-dose))939.56 ± 50.791922.38 ± 34.90
Week 17 (4 h (post-dose))842.31 ± 62.221750.70 ± 53.32
Week 17 (6 h (post-dose))759.88 ± 63.431673.95 ± 41.53
Week 21 (0 h (pre-dose))707.49 ± 63.581547.41 ± 63.92
Week 33 (0 h (pre-dose))702.67 ± 93.111477.60 ± 74.80
Week 45 (0 h (pre-dose))697.92 ± 76.021368.87 ± 79.60
Week 57 (0 h (pre-dose))559.17 ± 117.271257.42 ± 78.96
Wek 69 (0 h (pre-dose))530.91 ± 154.331355.91 ± 89.03
SecondaryOverall Survival (OS)

OS is defined as the time from date of randomization to date of death due to any cause or the last date that a patient was known to be alive (censored observation) as of the data cut-off.

Time frame:
42 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsLDE225 200mg laBCCLDE225 800mg laBCCLDE225 200mg mBCCLDE225 800mg mBCC
Overall Survival (OS)NA (NA to NA)NA (NA to NA)47.6 (NA to NA)33.8 (NA to NA)

Adverse events

Collected over Adverse events and serious adverse events were collected for the maximum actual duration of treatment exposure and follow up for a participant per the protocol for approximately 76.2 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LDE225 200 mg qd1/79 (1.3%)16/79 (20.3%)76/79 (96.2%)
LDE225 800 mg qd7/150 (4.7%)58/150 (38.7%)145/150 (96.7%)
Most frequent serious events
Showing 10 of 104
Most frequent serious events
EventLDE225 200 mg qdLDE225 800 mg qd
Blood creatine phosphokinase increasedInvestigations1/796/150
AnaemiaBlood and lymphatic system disorders0/795/150
RhabdomyolysisMusculoskeletal and connective tissue disorders1/795/150
VomitingGastrointestinal disorders0/794/150
PneumoniaInfections and infestations2/793/150
NauseaGastrointestinal disorders0/793/150
DehydrationMetabolism and nutrition disorders1/793/150
DiarrhoeaGastrointestinal disorders0/792/150
Small intestinal obstructionGastrointestinal disorders0/792/150
Abscess limbInfections and infestations0/792/150
Most frequent other events
Showing 10 of 42
Most frequent other events
EventLDE225 200 mg qdLDE225 800 mg qd
Muscle spasmsMusculoskeletal and connective tissue disorders43/79104/150
DysgeusiaNervous system disorders35/7989/150
AlopeciaSkin and subcutaneous tissue disorders39/7987/150
NauseaGastrointestinal disorders31/7971/150
Weight decreasedInvestigations24/7964/150
FatigueGeneral disorders26/7955/150
Blood creatine phosphokinase increasedInvestigations23/7954/150
Decreased appetiteMetabolism and nutrition disorders18/7952/150
DiarrhoeaGastrointestinal disorders25/7934/150
MyalgiaMusculoskeletal and connective tissue disorders15/7942/150

Baseline characteristics

The full analysis set (FAS) comprised all patients who were assigned study treatment irrespective of receiving it (all randomized patients). Patients were classified according to the treatment they were assigned in accordance with the intention-to-treat (ITT) principle.

Age, Continuous
Age, Continuous(Years)LDE225 (Sonidegib) 200 mgLDE225 (Sonidegib) 800 mgTotal
Mean65.6 ± 15.6763.6 ± 14.5964.3 ± 14.96
Sex: Female, Male
Sex: Female, Male(Participants)LDE225 (Sonidegib) 200 mgLDE225 (Sonidegib) 800 mgTotal
Female315586
Male4896144
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LDE225 (Sonidegib) 200 mgLDE225 (Sonidegib) 800 mgTotal
Black011
Caucasian71145216
Other8513
08

Study locations

62 sites
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • University of California at Los Angeles UCLA 3
    Los Angeles, California 90095, United States
  • Stanford University Medical Center Stanford Univ 2
    Stanford, California 94304, United States
  • University of Colorado School of Medicine UC
    Aurora, Colorado 80045, United States
  • Washington Hospital Center Wash Hospital
    Washington, District of Columbia 20010, United States
  • H Lee Moffitt Cancer Center and Research Institute Cutaneous Onc Dept
    Tampa, Florida 33612, United States
  • NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Study coordinator
    Chicago, Illinois 60611, United States
  • Dana Farber Cancer Institute DFCI - MA
    Boston, Massachusetts 02215, United States
  • Henry Ford Hospital Henry Ford
    Detroit, Michigan 48202 2689, United States
  • Washington University School Of Medicine-Siteman Cancer Ctr Siteman
    Saint Louis, Missouri 63110, United States
  • Comprehensive Cancer Centers of Nevada CCC of Nevada- Southwest (2)
    Las Vegas, Nevada 89109, United States
  • Hackensack University Medical Center Hackensack (SC)
    Hackensack, New Jersey 07601, United States
  • New York University Medical Center SC-2
    New York, New York 10016, United States
  • Penn State University / Milton S. Hershey Medical Center Hershey Medical
    Hershey, Pennsylvania 17033-085, United States
  • University of Pittsburgh Medical Center UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology
    Dallas, Texas 75246, United States
  • Texas Oncology Tex Onc 3
    Dallas, Texas 75246, United States
  • Texas Oncology Texas Onc - Amarillo
    Dallas, Texas 75246, United States
  • University of Texas MD Anderson Cancer Center MD Anderson
    Houston, Texas 77030, United States
  • Texas Oncology Cancer Care & Research Center
    Waco, Texas 76712, United States
  • Texoma Cancer Center Texoma Cancer Center
    Wichita Falls, Texas 76310, United States
  • University of Utah / Huntsman Cancer Institute Huntsman/Univ UT
    Salt Lake City, Utah 84103, United States
  • Novartis Investigative Site
    St Leonards, New South Wales 2065, Australia
  • Novartis Investigative Site
    Geelong, Victoria 3220, Australia
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Wilrijk, 2610, Belgium
  • Novartis Investigative Site
    Waterloo, Ontario N2J 1C4, Canada
  • Novartis Investigative Site
    Sainte-Foy, Quebec G1V 4T3, Canada
  • Novartis Investigative Site
    Lyon Cedex, 69373, France
  • Novartis Investigative Site
    Marseille Cedex 05, 13885, France
  • Novartis Investigative Site
    Pierre Benite Cedex, 69495, France
  • Novartis Investigative Site
    Toulouse Cedex 9, 31059, France
  • Novartis Investigative Site
    Villejuif Cedex, 94805, France
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Gera, 07548, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Muenchen, 81377, Germany
  • Novartis Investigative Site
    Muenster, 48157, Germany
  • Novartis Investigative Site
    Stade, 21682, Germany
  • Novartis Investigative Site
    Athens, 161 21, Greece
  • Novartis Investigative Site
    Budapest, H-1085, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Szeged, H-6725, Hungary
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Napoli, 80131, Italy
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Geneve, 1211, Switzerland
  • Novartis Investigative Site
    Zürich, 8091, Switzerland
  • Novartis Investigative Site
    High Heaton, Newcastle Upon Tyne NE7 7DN, United Kingdom
  • Novartis Investigative Site
    Yeovil, Somerset BA21 4AT, United Kingdom
  • Novartis Investigative Site
    Cardiff, CF14 4XW, United Kingdom
  • Novartis Investigative Site
    Glasgow, G3 8SJ, United Kingdom
  • Novartis Investigative Site
    Leicester, LE1 5WW, United Kingdom
  • Novartis Investigative Site
    London, EC1A 7BE, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9WL, United Kingdom
09

References and documents

Publications

  • Gutzmer R, Robert C, Loquai C, Schadendorf D, Squittieri N, Arntz R, Martelli S, Dummer R. Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. BMC Cancer. 2021 Nov 19;21(1):1244. doi: 10.1186/s12885-021-08968-1. PubMed 34798846 ↗
  • Lewis K, Dummer R, Farberg AS, Guminski A, Squittieri N, Migden M. Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial. Dermatol Ther (Heidelb). 2021 Dec;11(6):2225-2234. doi: 10.1007/s13555-021-00619-4. Epub 2021 Oct 20. PubMed 34669179 ↗
  • Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, Dirix L, Combemale P, Stratigos A, Plummer R, Castro H, Yi T, Mone M, Zhou J, Trefzer U, Kaatz M, Loquai C, Kudchadkar R, Sellami D, Dummer R. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):372-381. doi: 10.1111/jdv.14542. Epub 2017 Nov 6. PubMed 28846163 ↗
  • Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornelis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun;16(6):716-28. doi: 10.1016/S1470-2045(15)70100-2. Epub 2015 May 14. PubMed 25981810 ↗

Individual participant data

Plan to share: Yes

Access criteria: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2011 to primary completion in Jun 2013, 23 months.

Results were first posted in Nov 2015, 2 years 4 months after primary completion.

Of 43 phase 2 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 67. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2011
First posted
Apr 1, 2011
StartActual
Jun 29, 2011
Primary completionActual
Jun 28, 2013
CompletionActual
Jun 29, 2018
Results first posted
Nov 23, 2015
Last update
Aug 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01327053
Responsible party
Sponsor
First posted
Apr 1, 2011
Start date
Jun 29, 2011
Primary completion
Jun 28, 2013
Completion
Jun 29, 2018
Results posted
Nov 23, 2015
Last update
Aug 28, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonidegib

Start the discussion